

Review of: "Personalized (tailored) treatment with antiresorptive drugs (bisphosphonates, denosumab) in patients with bone metastases from solid tumors – A “Pico” document by Rete Oncologica Piemonte-Valle D’Aosta Bone Metastatic Disease Study Group"

Valesca Koth¹

¹ Pontifícia Universidade Católica do Rio Grande do Sul

Potential competing interests: No potential competing interests to declare.

Thank you for the opportunity of reviewing this paper, it is a very interesting study. This study makes a translation of an Italian guideline to English language in which antiresorptive therapies are evaluated in order to define if it is possible to institute a tailored/personalized treatment to patients instead of applying the same protocol to everyone. The aim of a personalized treatment would be to reduce adverse effects and to increase the patient's compliance.

Among the adverse effects cited in the paper, there is a description of medication related osteonecrosis of the jaws (MRONJ), in which the authors attribute this disorder specifically to treatment features: "The duration of treatment, the cumulative dose of the drug administered, and the observation time would seem fundamental for the MRONJ risk". The authors explain that zoledronic acid administration with longer periods of interval may reduce the risk of MRONJ. However, it is well known that local and systemic aspects of the patient are important risk factors to MRONJ (such as periodontal disease, tooth extraction, smoking, anemia, diabetes). It would be interesting if the authors discuss the possibilities of increasing the interval between the drug infusions (quarterly x monthly) in patients with high risk of MRONJ due to local and systemic risk factors, therefore this is my suggestion to this paper.